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Cancer is considered the most aggressive malignancy to humans, and definitely the
major cause of death worldwide. Despite the different and heterogenous presentation
of the disease, there are pivotal cell elements involved in proliferation, differentiation,
and immortalization, and ultimately the capability to evade treatment strategies. This is
of utmost relevance when we are just beginning to grasp the complexity of the tumor
environment and the molecular “evolution” within. The tumor micro-environment (TME)
is thought to provide for differentiation niches for clonal development that results in
tremendous cancer heterogeneity. To date, conventional cancer therapeutic strategies
against cancer are failing to tackle the intricate interplay of actors within the TME.
Nanomedicine has been proposing innovative strategies to tackle this TME and the
cancer cells that simultaneously provide for biodistribution and/or assessment of action.
These nanotheranostics systems are usually multi-functional nanosystems capable to
carry and deliver active cargo to the site of interest and provide diagnostics capability,
enabling early detection, and destruction of cancer cells in a more selective way. Some
of the most promising multifunctional nanosystems are based on gold nanoparticles,
whose physic-chemical properties have prompt for the development of multifunctional,
responsive nanomedicines suitable for combinatory therapy and theranostics. Herein, we
shall focus on the recent developments relying on the properties of gold nanoparticles
as the basis for nanotheranostics systems against the heterogeneity within the TME.
Keywords: tumor microenvironment, nanomedicine, cancer therapy, diagnostic, gold nanoparticles,
nanotheranostics
INTRODUCTION
As the knowledge about cancer development progresses, it highlights the complexity of the disease
characterized by inter-tumor and intra-tumor heterogeneity between cancer types of different or
the same anatomical region (Mroz and Rocco, 2016; Grzywa et al., 2017; Liu et al., 2018a). This
interplay between growing tumor cells and surrounding environment creates a tumor micro-
environment (TME), whose arrangement varies according to the anatomical region of the tumor
and the genetic and phenotypic traits of cancer cells (Correia and Bissell, 2012; Abadjian et al.,
2017). Still, several common features can be found, such as the micro-environment of epithelial
tumors is generally composed by tumor cells, the extracellular matrix (ECM), stromal cells,
including fibroblasts, mesenchymal stromal cells, cells from the blood and lymphatic systems,
and occasionally adipocytes and cells from the immune system, including macrophages, T and B
lymphocytes, and natural killer cells.
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TME composition and maturation dictates tumor
progression, prognosis and the efficacy of chemotherapeutics,
where it is becoming more evident that one therapy does
not fit all (Netea-Maier et al., 2018). That is why a thorough
comprehension of a patient’s TME may provide for important
clues of the most effective therapeutics. For this, efforts have been
made to develop imaging and therapeutic strategies focused on
TME for improving the efficacy of treatment (Roma-Rodrigues
et al., 2019). Perhaps the most innovative and effective strategies
have been put forward by nanomedicine, that offers a vast
number of diagnostics and therapeutics, alone or combined
into a single platform, in what is known as nanotheranostics.
The Medical Standing Committee of the European Science
Foundation states that “Nanomedicine is the science and
technology of diagnosing, treating, and preventing disease
and traumatic injury, of relieving pain, and of preserving and
improving human health, using molecular tools, and molecular
knowledge of the human body.” The last decades have fueled the
synthesis and assembly of a plethora of nanomaterials, such as
nanoparticles made of noble metals, carbon, heavy metals, etc.,
in many forms, e.g., spherical or non-spherical nanoparticles,
nanowires, nanotubes and nanofilms. These nanomaterials have
got unique properties that might be explored for theranostics
applications. For example, carbon nanotubes are excellent
conductors, with exceptional strength; iron oxide nanoparticles
are superparamagnetic; while gold nanoparticles have unique
spectral (optical) properties (reviewed in Pedrosa et al., 2015;
Elzoghby et al., 2016; Bhise et al., 2017; Bayda et al., 2018).
These nanostructures’ primary advantages for biomedical
applications are the small size within the same scale than
that of biomolecules and an augmented area-to-volume ratio
Abbreviations: AGF, anterior gradient 2; AIPH, 2,2
′
-azobis[2-(2-imidazolin-
2-yl) propane] dihydrochloride; AMC, 7-amino-4-methylcoumarin; AuNC,
gold nanocage; AuNP, gold nanoparticle; AuNR, gold nanorod; AuNR@MSN,
mesoporous silica coated nanorod; bFGF, basic fibroblast growth factors; BSA,
bovine serum albumin; CAFs, cancer associated fibroblasts; CD, cyclodextrin;
CS, chitosan oligosaccharide; CSC, cancer stem cell; CT, computed tomography;
DAMPs, damage-associated molecular patterns; DMA, 2,3-dimethylmaleic
anhydride; DOX, doxorubicin; ECM, extracellular matrix; EGF, epithelial growth
factor; EMT, epithelial-to-mesenchymal transition; EPR, enhanced permeability
retention; FL, fluorescence; GM-CSF, granulocyte-macrophage colony stimulating
factor; HA, hyaluronic acid; HB-GFs, heparin-binding growth factors; HIF,
hypoxic-induced factor; HM, humanized mice; HTS, high throughput screening;
ICG, indocyanine green; IL, interleukin; LECs, lymphatic endothelial cells;
LSC, 4-(2-(5-(1,2-dithiolan-3-yl)pentanamido)ethylamino)-2methyl-4-oxobut-2-
enoic acid; MDR,multidrug resistance; MDSCs, myeloid-derived suppressive cells;
MET, mesenchymal-to-epithelial transition; MMPs, matrix metalloproteinases;
MRI, magnetic resonance imaging; MSA, mouse serum albumin; MSOT,
multispectral optoacoustic tomography; NIR, near infrared; NIRF, near infrared
fluorescence; NK, natural killer; OoC, organ-on-a-chip; PAI, photoacoustic
imaging; PCM, phase-change material; PDC, patient derived xenografts; PDT,
photodynamic therapy; PEG, poly-ethylene glycol; PlGF, placental growth
factor; PTT, photothermal therapy; RCA, rolling circle amplification; RNS,
reactive nitrogen species; ROS, reactive oxygen species; SERS, surface-enhanced
Raman scattering; TAMs, tumor associated macrophages; TCDEs, tumor
cells derived exosomes; TGF-β, transforming growth factor beta; TME,
tumor microenvironment; TNF, tumor necrosis factor; ToC, tumor-on-a-chip;
TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; VEGF, vascular
endothelial growth factor; VEGFR, vascular endothelial growth factor receptor;
VPF, vascular permeability factor.
allowing an increased interphase area in a small mass (Pedrosa
et al., 2015; Elzoghby et al., 2016; Bhise et al., 2017; Bayda
et al., 2018). One crucial advantage of nanoparticles for
cancer therapy is their tendency to naturally accumulate
within tumors via enhanced permeability retention (EPR;
Nichols and Bae, 2014). The fundamental features of EPR
are hyperpermeability of tumor vasculature to large particles
(enhanced permeability) and impaired lymphatic drainage,
retaining the particles into the interstitial space of the tumor
(enhanced retention) (Nichols and Bae, 2014). This way,
nanomaterials passively accumulate at tumors’ sites where they
can then exert their therapeutic/diagnostic effect. In order to
extravasate the vasculature and avoid renal filtration and liver
capture, nanoparticles should range between 10 and 100 nm
and preferably present a neutral or anionic charge (Danhier
et al., 2010; Dreaden et al., 2012). Using the EPR to passively
accumulate nanoconjugates at the tumor site has been thoroughly
described in a general way. However, tumors are heterogeneous,
impacting the capacity of nanoparticles to homogeneously
penetrate the neoplastic tissue (Danhier, 2016). For example,
larger particles (100 nm) have higher retentions times in the
tumor (Danhier et al., 2010). Also, the EPR based accumulation
varies greatly with the degree of vascularization, which is not
always easy to predict (Danhier et al., 2010). There are also several
tumor types that do not preset an EPR effect that can be used,
such as prostate and pancreatic tumors (Danhier et al., 2010).
Another limitation of passive targeting relying solely on EPR
is the inability of passive targeting to access necrotic tissue, in
the core of the tumor due to the low vascularization (Ngoune
et al., 2016). These disadvantages can be overcome with different
strategies, for instance, using drugs to modulate vascularization.
For example, vasoconstriction drugs cause normal vessels
constriction, but tumor vessels do not respond to this effect due
to insufficient muscular structure, which leads to an increased
uptake of particles by tumor tissues (Maeda, 2012). To overcome
limitation imposed by using EPR alone, several strategies include
active targeting by means of several moieties (e.g., antibodies or
peptides), capable to promote ligand-receptor interactions at the
surface of tumor cells, inducing receptor-mediated endocytosis
and drug release inside the cell (Kobayashi et al., 2014). Such
moieties include, for example, EGFR, TGF-α, folate, or glucose
receptors, which are known to be overexpressed in cancer
cells. Active targeting has been critical for the development of
vectorization systems that enable the nanoparticles to deliver
their cargo on tumor site improving the therapeutic effect
(Dreaden et al., 2012). Among the variety of nanomaterials,
spherical gold nanoparticles (AuNPs) have been extensively
studied for cancer diagnosis and treatment, mostly due to their
unique optical properties, easy synthesis in aqueous solution,
and functionalization with biomolecules, which together have
not presented toxicity to the cells and organisms (Conde
et al., 2014). AuNPs can be easily functionalized with different
moieties, such as drugs, targeting ligand, protein or peptides,
nucleic acids, imaging agents, photosensitizers, bioactive/bio-
responsive moieties, among others. Targeting ligands bound to
the surface of nanoparticles interact with receptors selectively
expressed in tumor cells (Haume et al., 2016). By means of
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targeting ligands, it is possible to profit from the EPR effect to
accumulate the AuNPs in the tumor site and then direct the
gold nanoconjugates selectively to cancer cells. This way the
anti-tumor effect may be delivered solely (or mostly) to the
malignant cells while sparing the healthy tissues, thus with a
beneficial impact in decreasing side effects (Guo et al., 2017).
In addition, bioactive/bio-responsive moieties can be sensitive
to TME and respond to specific stimuli, such as pH or matrix
metalloproteinase (MMP; Guo et al., 2017). Chemotherapeutics
drugs may also be loaded onto or attached to the surface of
nanoparticles, thus functioning as carriers (Singh et al., 2018).
Besides the possible functionalization of AuNPs to a specific
TME target, naked AuNPs were found to disrupt the crosstalk
between cells within the TME and, consequently, preventing
tumor progression. For example, AuNPs were found to influence
angiogenesis by diminishing both the tube formation and
migration of endothelial cells, through blockage of vascular
endothelial growth factor (VEGF) signaling from TME cells
to endothelial cells (Zhang Y. et al., 2019). Also, AuNPs have
been found to promote tumor vasculature normalization while
increasing blood perfusion and reducing hypoxia (Li et al.,
2017). These basic AuNP systems may also be used to improve
imaging approaches to assist surgeons during tumor resection,
by injecting functionalized AuNPs specifically into the tumor it
is possible to distinguish between healthy and malignant cells
(Singh et al., 2018).
TUMOR MICROENVIRONMENT
Despite the growing knowledge of tumor development and
progression, it is virtually impossible to determine cause-effect
chain of events, from the initial stage when cells become
tumorigenic and initiate uncontrolled proliferation, to a mature
high-grade tumor. Sometimes one is tempted to associate one
event triggered by proliferating tumor cells to an event occurring
within the TME, but this correlation falls far from reality since it
is the evolving interplay of all TME components that ultimately
will be responsible for tumor modulation and progression
(Hanahan and Weinberg, 2011; Netea-Maier et al., 2018). Here
we shall focus on each component of the TME separately for
simplicity. However, it is crucial to understand that each one of
these events, occurring for each component, may be triggered in
a different way for a different tumor or tumor type, thus affect
all the other TME components differently, and consequently
resulting in different outcomes. Figure 1 and Table 1 highlight
the major events occurring at the TME that contribute for
tumor progression.
The rapid proliferation of tumor cells results in a constrain
in oxygen and nutrient supply that cannot be sustained by
adjacent blood vessels (Hanahan and Weinberg, 2011). The
oxygen scarcity experienced by growing tumor cells induce the
cellular response to hypoxia, principally via hypoxia-induced
factors (HIF) (reviewed in Vaupel and Multhoff, 2018). The
HIF family of transcriptional factors is composed by HIF1,
HIF2 and HIF3 proteins that activate genes involved in glucose
metabolism, angiogenesis, cell proliferation and migration, and
immune system modulation (Huang et al., 2017; Sormendi and
Wielockx, 2018; Vaupel and Multhoff, 2018). The HIF response
together with high energetic requirements, trigger a metabolic
adjustment in tumor cells from oxidative phosphorylation to
the aerobic glycolysis, in a process known as the Warburg
effect (Gwangwa et al., 2018). This metabolic switch subsists
even in the presence of oxygen and results in an increased
secretion of lactate to the extracellular space and consequent
TME acidification (Lu, 2019). The glycolytic metabolism and
intensified proliferation of tumor cells result in an increase
of reactive oxygen species (ROS) production, which in turn
target cellular components, such as DNA, promoting genomic
instability that further alters the cells’ characteristics, and also
induces the activation of antioxidant defenses (Gwangwa et al.,
2018). These events, together with increased expression of efflux
pumps for lactic and carbonic acid secretion gives an advantage
to tumor cells to survive and thrive in hostile environments,
contributing for multidrug resistance (MDR; Tsai et al., 2014).
Interestingly, rather than oncogenic promoters in malignant
cells, HIF proteins act as tumor suppressors (Mazumdar et al.,
2010; Lee et al., 2016; Nakazawa et al., 2016). However, HIF-
mediated paracrine communications between tumor cells and
neighborhood, including stromal cells, immune system cells,
metastases and extracellular matrix modulation, promote tumor
development, rendering oncogenic features to HIF proteins at
the TME level (reviewed in Huang et al., 2017; Sormendi and
Wielockx, 2018).
The secretion of vascular endothelial growth factor A
(VEGFA) by TME components, promote the sprouting of
adjacent vessels through binding to VEGF receptors (VEGFR)
located in endothelial cells (De Palma et al., 2017; Klein,
2018). The high levels of angiogenic signals at the TME, lead
to the formation of vessels with defective or discontinuous
basement membranes, resulting in the leaking vasculature with
chaotic organization unevenly distributed along the tumor,
with cancer regions enriched with vessels and cancer regions
poorly supplied (Klein, 2018). This restricts the nutrient and
oxygen supply to the TME, promoting hypoxia, and difficult
the chemotherapeutic agents’ distribution throughout the tumor
(Klein, 2018). Moreover, the unbalanced distribution of blood
vessels results in an altered distribution of cytokines involved
in inflammatory and coagulation processes at the TME (Klein,
2018). Nevertheless, it is this less organized leaky vasculature that
allows nanomedicines to passively target the tumor site.
The formation of lymphatic vessels at the TME, named
tumor-associated lymphangiogenesis, is sustained by VEGF-C
and VEGF-D secreted by tumor cells, immune cells, and other
stromal cells (Garnier et al., 2019). Then, lymphatic endothelial
cells (LECs) form single layer lymph capillaries with minimal
basement membrane, that join to collecting lymphatic vessels
with a basement membrane and valves that prevent retrograde
flow (Garnier et al., 2019). The formation of lymphatic vessels
at the TME is correlated with poor prognosis, since it favors
metastatic propagation in distal organs (Garnier et al., 2019). On
the other side, LECs have a prominent role in immune system
modulation at the TME contributing for anti-tumor immunity
(reviewed in Farnsworth et al., 2019; Garnier et al., 2019).
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FIGURE 1 | The complex context of tumor microenvironment. Schematic reorientation highlighting the diversity of elements within the tumor micro-environment
(TME). The features and composition of a late stage solid TME are extremely heterogeneous with high intra- and inter-tumor variability. Common features include the
appearance of hypoxic regions usually at the core of the tumor indicated as a denser cell population. Hypoxia is usually associated to decreased interstitial pH and
induces angiogenesis, resulting in an uneven distribution of blood vessels along the TME. Lymphatic vessels are also frequently found in tumor late stages. The
increased vasculature at the TME contribute for local invasion, the dissemination of cancer stem cells and formation of metastasis. The inflammatory environment
recruits mesenchymal stromal cells and innate system tumor cells. Tumor associated macrophages usually infiltrate the tumor and promote a pro-inflammatory
microenvironment contributing for tumor growth and reinforcing input for angiogenesis. Adaptive immune system cells are mainly found at the TME margins. The
inflammatory environment stimulates transformation of fibroblasts into cancer associated fibroblasts that, together with an alteration of the extracellular matrix
stiffness, contribute for increased desmoplasia at the TME and hence induce metastasis.
Again, the defective lymph drainage assists the accumulation of
nanomedicines at the locus via the EPR.
Concerning immune system cells, the TME varies
considerably throughout the tumor development and throughout
the various types of cancers (Netea-Maier et al., 2018). Due to
the continuous changes and adaptations occurring at the TME,
different recruitment factors (e.g., cytokines and chemokines)
are secreted, resulting in the enrollment of cells from both
innate and adaptive immune systems (Chen and Mellman, 2017;
Clark, 2018). Importantly, the molecular signals composition
of the TME determine the clinical outcome by promoting
the tumor escape to immunosurveillance or tumor constrain
(Netea-Maier et al., 2018). Once in the TME, monocytes can
differentiate into two different types of macrophages depending
on the chemical composition at the tumor location, the M1-type
macrophages are formed in the presence of interferon gamma
(IFN-γ), and the M2-type macrophages when exposed to
different interleukins (IL, e.g., IL-4 or IL-10), transforming
growth factor beta (TGF-β), Granulocyte-macrophage colony
stimulating factor (GM-CSF), annexin A1 or tumor cell-surface
molecules (reviewed in Italiani and Boraschi, 2014; Goswami
et al., 2017). This macrophages polarization is crucial for tumor
prognosis, as M1-type are correlated with a good prognosis,
while tumor associated macrophages (TAMs) generally have the
M2 phenotype and contribute for tumor growth, angiogenesis,
invasion, and metastasis (Italiani and Boraschi, 2014; Goswami
et al., 2017; Jeong et al., 2019; Prenen and Mazzone, 2019).
Inflammation is usually displayed in TME, promoted initially by
tumor cells (intrinsic pathway) and sustained and/or aggravated
by other TME components (reviewed in Mantovani et al.,
2019). A pro-inflammatory environment is usually accompanied
by a poor prognosis (reviewed in Netea-Maier et al., 2018;
Mantovani et al., 2019). The TAMs-mediated secretion of IL-1
cytokines contribute for chronic inflammation and strengthen
a pro-tumoral micro-environment (reviewed in Mantovani
et al., 2018). The role of the lymphoid lineage cells in tumor
progression is also contradictory. While B cells and regulatory
T cells create an immunosuppressive microenvironment, innate
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TABLE 1 | Tumor microenvironment components and their major effects on tumor development.
TME components Major effect on tumor development Disease
prognosis
References
Hypoxia HIF activation Poorer Vaupel and Multhoff, 2018
HIF loss of function Poorer Mazumdar et al., 2010; Lee
et al., 2016; Nakazawa et al.,
2016
HIF mediated paracrine TME communication Poorer Huang et al., 2018; Sormendi
and Wielockx, 2018
Aerobic glycolysis (Warburg effect) TME acidification Poorer Lu, 2019
Reactive Oxygen Species Poorer Gwangwa et al., 2018
Genomic instability Poorer Gwangwa et al., 2018
Activation of antioxidation defenses Poorer Gwangwa et al., 2018
Lymphoangiogenesis VEGF secretion in TME Poorer Garnier et al., 2019
Formation of lymph vessels by LECs Poorer Garnier et al., 2019
Activation of the Immune system Impairment of anti-tumor immunity through LECs loss of function Poorer Farnsworth et al., 2019; Garnier
et al., 2019
M1-type monocytes activation through IFN-γ, etc. Better Italiani and Boraschi, 2014;
Goswami et al., 2017; Jeong
et al., 2019; Prenen and
Mazzone, 2019
M2-type monocytes (also known as TAM) activation through IL-4,
IL-10, TGF-β, GM-CSF, Annexin A1, etc.
Poorer Italiani and Boraschi, 2014;
Goswami et al., 2017
Inflammation TAM mediated chronic inflammation in TME Poorer Mantovani et al., 2018
Activation of B and regulatory T lymphocytes Better DeNardo et al., 2010; Hui and
Chen, 2015; Labiano et al.,
2015; Wu, 2017; Steven and
Seliger, 2018
Activation of NK and NK T lymphocytes Poorer DeNardo et al., 2010; Hui and
Chen, 2015; Labiano et al.,
2015; Wu, 2017; Steven and
Seliger, 2018
GM-CSF and VEGF mediated production of MDSCs Poorer Schupp et al., 2017; Bruno et al.,
2019
Altered ECM Desmoplasia and metastatic dissemination Poorer Pickup et al., 2014; Kai et al.,
2019
Mesenchymal Stem Cells recruitment to TME Either
depending on
TME
Trivanovic et al., 2016;
Rivera-Cruz et al., 2017
CAF differentiation through inflammation and TGF-β Poorer Liu T. et al., 2019; Sanford-Crane
et al., 2019; Yoshida et al., 2019
Desmoplasia Induction of EMT and the formation of Cancer Stem Cells Poorer Kang et al., 2019; Pearson,
2019; Vahidian et al., 2019
Activation of MMPs in EMT Poorer Yao et al., 2018
Exosomes Autocrine and paracrine communications between tumor cells and
TME
Poorer Hannafon and Ding, 2013;
Franzen et al., 2014;
Roma-Rodrigues et al., 2014,
2017a
Autocrine and paracrine communications between normal cells and
TME
Better Hannafon and Ding, 2013;
Franzen et al., 2014;
Roma-Rodrigues et al., 2014,
2017a
HIF, hypoxia induced factor; TME, tumor microenvironment; VEGF, vascular endothelial growth factor; LECS, lymphatic endothelial cells; IFN, interferon; TAM, tumor associated
macrophages; IL, interleukin; TGF, tumor growth factor; GM-CSF, granulocyte-macrophage colony stimulating factor; NK, natural killer; MDSCs, myeloid-derived suppressive cells;
CAF, cancer associated fibroblasts; EMT, epithelial to mesenchymal transition.
cytotoxic lymphocytes, natural killer (NK) cells and NKT cells
contribute for an immunostimulant TME (DeNardo et al., 2010;
Hui and Chen, 2015; Labiano et al., 2015; Wu, 2017; Steven
and Seliger, 2018). In different types of cancers, the increased
expression of GM-CSF and VEGF induce the production
of myeloid-derived suppressive cells (MDSCs) at the bone
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marrow that are recruited to the TME where they remain
undifferentiated (reviewed in Bruno et al., 2019). The presence
of MDSCs is generally correlated with a poor prognosis, as they
are involved in angiogenesis, and suppression of NK cells and
CD8+ cytotoxic T cells (Schupp et al., 2017; Bruno et al., 2019).
In epithelial cancers, growing tumor cells and TME cell
components are supported in an ECM with altered biochemical
and biomechanical properties when comparedwith healthy tissue
(reviewed in Pickup et al., 2014; Kai et al., 2019). The low
oxygenation and inflammatory environment induce alterations
in ECM proteins that result in desmoplasia, characterized by
increased stiffness (Pickup et al., 2014; Kai et al., 2019). The
ECM major contributors for desmoplasia include collagen types
I, III, and IV, fibronectin, laminin, hyaluronic acid (HA) and
osteonectin (Whatcott et al., 2011).
Stromal cells are also important for tumor development and
prognosis. Mesenchymal stromal cells (MSCs) are recruited to
the tumor due to the inflammatory environment and, according
to the chemical composition at the TME they may promote or
inhibit the tumor progression (reviewed in Trivanovic et al.,
2016; Rivera-Cruz et al., 2017). Moreover, the inflammation
and consequent secretion of TGF-β at the TME, induce the
differentiation of fibroblasts into cancer associated fibroblasts
(CAFs) (reviewed in Liu T. et al., 2019; Sanford-Crane et al.,
2019; Yoshida et al., 2019). Besides tumor cells, CAFs are the
most abundant cell type at the TME and play an important
role in increased desmoplasia of the TME (Liu T. et al., 2019;
Sanford-Crane et al., 2019; Yoshida et al., 2019).
Hypoxia, increased desmoplasia and the interactions between
the several TME players favor the epithelial-to-mesenchymal
transition (EMT) of tumor cells resulting in the formation
of cancer stem cells (CSC) (reviewed in Kang et al., 2019;
Pearson, 2019; Vahidian et al., 2019). EMT results in disruption
of intracellular adhesion and loss of cell polarity, conferring
migratory ability to CSC that could enter in adjacent blood
or lymph vessels at the TME and travel to another anatomical
location where they can experience mesenchymal-to-epithelial
transition (MET) and potentiate the formation of a metastatic
niche (Kang et al., 2019; Pearson, 2019; Vahidian et al., 2019).
Matrix metalloproteinases (MMPs) have an important role in
EMT, being responsible for the detachment of tumor cells from
the ECM promoting CSC formation (Yao et al., 2018).
During the initial stages of tumorigenesis, the genomic profile
of tumor cells determines the tumor maturation. As the cancer
progresses, the intercellular communication between tumor
and neighboring cells dictates TME and tumor progression,
contributing for intra- and inter-tumor heterogeneity (Hanahan
and Weinberg, 2011; Netea-Maier et al., 2018). Exosomes
are pivotal for the cell to cell communication. Exosomes are
endosomal pathway derived vesicles with 30–100 nm diameter,
composed by a lipid bilayer with membrane proteins, entrapping
soluble proteins, signaling molecules, including cytokines,
chemokines and growth factors, and nucleic acids including
mRNA and miRNA (Roma-Rodrigues et al., 2014). Importantly,
exosomes’ content depends on the cell of origin, often reflecting
the physiological condition of the cell (Hannafon and Ding,
2013). After released to the extracellular milieu, exosomes can
be internalized by secondary cells adjacent to the primary cell
or travel through the vascular or lymphatic system to other
anatomical location where they can be internalized by local cells.
Once internalized, exosomes are able to modify the phenotype of
the recipient cell that will adjust to the incoming signals (Franzen
et al., 2014; Roma-Rodrigues et al., 2017a). Tumor cells derived
exosomes (TCDEs) have an important role in tumor progression,
including for example in immune system modulation,
contributing in normal to tumoral transition of adjacent
cells and preparation of the metastatic niche at a new anatomical
location (Chen et al., 2017; Roma-Rodrigues et al., 2017a).
As discussed, TME development is astonishingly similar
between types of cancer, exhibiting several common features in
composition and organization. However, TME features are also
highly dependent on tissue/organ. For example, hematological
cancers will show an increased angiogenesis at the TME site in
the bone marrow (reviewed in Cheng et al., 2018).
Notwithstanding the growing awareness of the role played by
the TME in tumorigenesis, tumor progression and metastasis
in the organism, most studies rely on in vitro data to build
models, simulate conditions, and for the screening of novel drugs.
What is more, most of these screenings and assessments are
made using traditional cell lines that only resemble the real
tumor in the individuals, letting the whole of intra- and inter-
tumor heterogeneity at large. One of the most relevant trends in
studying the effect novel diagnostics and therapeutic strategies
for cancer has prompt for the development of realistic in vitro
and ex vivomodels to substitute the expensive and variable in vivo
studies, thus allowing to speed up research in this critical field.
MODELING THE TME
Despite the amount of data from conventional in vitro models
that rely on two-dimensional (2D) cell cultures, solid tumors
are three-dimensional (3D) entities with cells growing on
heterogenous gradients of nutrients and oxygen, suffering from
various degrees of different chemical and physical stresses and
interacting with different types of cells (LaBarbera et al., 2012;
Weiswald et al., 2015). Therefore, promising drugs need to be
tested in pre-clinical models mimicking the TME, and recurring
to murine models with tumor xenografts, before they can get
approval for human trials (Ranga et al., 2014). This is an
expensive process that often fails to accurately predict therapeutic
responses due to the fundamental differences between animal
and human physiology. Only 5% of the compounds deemed
promising in the initial evaluations are successful in clinical
applications, which highlights the shortcomings of common
standard models used for routine drug screening (LaBarbera
et al., 2012; Ranga et al., 2014).
For assisting faster and more robust clinical translation,
several (cell) models have been proposed. For example,
humanized mice (HM) have been increasingly used to reduce the
gap between animal and humans. HM are genetically engineered
mice with human genes or human cells alongside the tumor
xenografts (Morton et al., 2016). Another increasingly used
pre-clinical model is patient derived xenografts (PDX) (Hidalgo
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et al., 2014). Mice xenografts produced directly from tumor
biopsies can be used to more accurately predict how patients
will respond to treatment and opens the door to personalized
therapeutics (Hidalgo et al., 2014). However, these animal
models are too expensive for high throughput screening (HTS)
of novel drugs or treatment vectorizations (Rodrigues et al.,
2018; Sasmita and Wong, 2018). For a long time, HTS has
strongly depended on primary screening made with 2D cultures
whose physiological and TME associated limitations have been
surpassed by the advent of 3D cell culture models. For instance,
cellular signal transduction pathways have been shown not
to properly be activated in 2D cultures. Moreover, sensitivity
to chemotherapeutic agents and induction of apoptosis are
impaired in cell lines grown in 2D monolayers due to the lack of
cell-cell and cell-extracellularmatrix interactions, that are present
in tissues and in 3D models (Kenny et al., 2007; Serebriiskii et al.,
2008; Yin et al., 2016; Reynolds et al., 2017; Riedl et al., 2017;
Buzzelli et al., 2018). Also, these models made possible the study
of angiogenesis within a tumor and the evaluate the importance
of the immune system in tumor growth (LaBarbera et al., 2012;
Ranga et al., 2014; Buzzelli et al., 2018).
The simplest 3D model are multicellular tumor spheroids, or
simply spheroids, obtained when adherent cell lines are grown
in non-adherent conditions. The cells form 3D structures similar
to in vivo tumors and are capable to recapitulate the TME
interactions that are crucial for in vivo development (Sutherland
et al., 1971; LaBarbera et al., 2012; Lancaster and Knoblich, 2014;
Ranga et al., 2014). At first, spheroids were grown with only
one cell line, however the complex nature of solid tumors led
to the development of more intricate systems, with two or more
different cell types, and thus able to mimic ECM, inter-cellular
signaling and in vivo growth (LaBarbera et al., 2012). These more
complex spheroids, with at least one tumor cell type, have been
called organoids. Although the term was originally developed for
spheroids grown from stem cells or organ progenitor cells, that
would grow and differentiate into different cell types resulting
in a spheroid with spatial auto-organization of different cell
types similarly to the organization found in vivo for the organ
from which they derive (Sung et al., 2008; LaBarbera et al.,
2012; Lancaster and Knoblich, 2014). Considering that, in this
filed, terminology is not consensual, we shall name spheroids
to those multicellular spheroids constituted with only one cell
type; multitype spheroids with at least one tumor cell line/type
will be named tumor organoids, while the others will be named
normal-type organoids.
In order to devise 3D systems that more accurately reflect the
molecular diversity of tumors and their respective TME, there
was a need for protocols to promote the growth of spheroids
and/or tumor organoids derived from cancer biopsies from
patients (Song et al., 2018; Vlachogiannis et al., 2018). These
patient derived tumor organoids are capable to recapitulate the
molecular profile of the patients’ tumors and have become a
valuable platform for HTS of compounds and for personalization
of therapy (van de Wetering et al., 2015; Vlachogiannis et al.,
2018). For example, AuNP have already been tested in some
of the novel systems constituted by A549, HEG2, S2PV10,
HCT116, and MCF7 cancer line spheroids so as to evaluate NP
penetration within the tridimensional structure (Huang et al.,
2012; England et al., 2013; Rane and Armani, 2016). Also, the
potential photothermal therapy effectiveness of AuNPs have
been evaluated on HeLa, normal ovarian cells, and human
umbilical vein endothelial cells (HUVEC) spheroids, and in HeLa
tumor organoids (Lee et al., 2018). Additionally, normal-type
organoids have been used to test potential nephrotoxicity of
AuNPs (Astashkina et al., 2014).
To further narrow the gap between in vitro and in vivomodels,
great efforts have been made to use microfluids platforms to
reproduce more accurately TME and normal tissue functions,
originating tissue-on-chip and organ-on-chip systems. The
first organ-on-a-chip models (OoC) presented cells capable to
replicate the physiological functions of the lung and heart within
a microfluidic device with appropriate channels, chambers and
mechanic movement (Huh et al., 2010; Annabi et al., 2013).
The combination of different cell types, from liver and skin,
within a multi-organ-chip, proved their potential in therapeutic
drug testing (Wagner et al., 2013). The use of cancer cell lines
on microfluidic devices led to the construction of tumor-on-a-
chip models (ToC), also called cancer-on-a-chip. These systems
have been shown to accurately mimic several features observed
in tumors, such as pressure, chemical and gas gradients and
fluidic shear stress, while being more amenable to HTS than
other previous 2D and 3D models (Bhatia and Ingber, 2014; Tsai
et al., 2017; Sleeboom et al., 2018; Shang et al., 2019). These
ToC have been successfully used to co-culture cancer cells with
endothelial cells, thus facilitating the study of the interplay in the
TME between vasculature and tumor cells (Sleeboom et al., 2018;
Shang et al., 2019). Also, these chip-based platforms have been
used to assess nanoparticles’ fate and action in more complex
models. For example, AuNPs have been tested in an OoC with
HUVEC to evaluate how endothelial thermotolerance could
affect nanoparticle transport to tumors (Bagley et al., 2015). ToCs
incorporating spheroids of MDA-MB-453 and MCF-7 cells were
used to study tissue penetration and cellular uptake of AuNPs
(Albanese et al., 2013; Kwak et al., 2014). Deeper insights into the
EPR effect have also been possible via a tumor-vasculature-on-a-
chip developed to study the perfusion of nanoparticles in an in
vitromodel (Wang H. F. et al., 2018).
It is based on these developing 3D complex models,
harboring different players from within the TME, that several
nanomedicines have been tested and evaluated, aiming at
eventually being translated to the clinics and providing additional
tools for the fight against cancer. Not surprisingly, these complex
3D and chip models have been crucial for the evaluation of
innovative approaches in tacking the TME, which, whole or in
part, make use of the one ormore of the elements within the TME
that modulate tumor growth and development.
TARGETING TME VIA GOLD
NANOPARTICLES
Several types of nanomaterials, and nanoparticles in particular,
have been proposed as tools to study and/or assist in the fight
against cancer. Amongst these nanoparticles, gold has emerged
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as a material of choice due to their spectral properties, ease of
synthesis and functionalization. Additionally, small (15–60 nm)
spherical AuNPs has not been shown to exhibit toxicity, which
has prompt for their use as valuable platforms for diagnostics
(e.g., imaging) and therapy. The interaction between AuNPs and
the TME is, thus, of crucial relevance toward the development
of innovative efficacious nanomedicines that could tackle tumors
alone or in combinatory approaches with more traditional
therapies. Table 2 summarizes the specific characteristics of the
TME to be targeted by AuNPs for diagnostic and/or therapy
in cancer.
Tackling the Acidic pH in the TME
Several features of TME can be used to target nanomedicines
to the tumor site for improved diagnosis and/or therapy.
For example, the acidic microenvironment may be used
to trigger responsive nanomedicines that release the cargo
upon pH stimuli. In this respect, citraconic amides are
moieties sensitive to pH, being hydrolyzed and converted in
positively charged primary amines that are suitable to act as
pH switches. Interaction with positive and negative charged
nanoparticles cause nanoparticle aggregation that could be
used for photoacoustic imaging, amplifying the signal and
blocking exocytosis. Nanosystems using the aggregation of
AuNPs induced by citraconic amides have been used as
a diagnostic tool (Song et al., 2016; Li et al., 2019). Song
et al. (2016) showed that an agent containing these amides
coupled to AuNPs accumulates specifically in cancer cells,
leading to an in vivo signal amplification that is the double
of that non-functionalized NPs (Song et al., 2016). Additional
functionalization may be added to the nanoplatform to also carry
a suitable chemotherapeutic drug, resulting in a theranostic agent
(Song et al., 2016). Li et al. (2019) created AuNPs functionalized
with 4-(2-(5-(1,2-dithiolan-3-yl)pentanamido)ethylamino)-
2methyl-4-oxobut-2-enoic acid (LSC) that contain the citraconic
amide moiety and a cyclic RGDyK peptide conjugated with 16-
mercaptohexadecanoic acid (c(RGDyK)MHDA) that allows the
active tumor-targeting due to the connection to overexpressed
integrin αvβ3 receptors (Li et al., 2019). Using a tumor-xenograft
mouse model, the conjugated molecules, LSC and c(RGDyK),
allowed for longer circulation times and enhanced accumulation
at the tumoral tissue, which then provided for optimized
photoacoustic signals at low concentration. Similar approaches
using fluorescence imaging (FL imaging) activated in the TME
due to the pH-sensitive structures have also been proposed to
assist diagnostics and biodistribution assessment (Lai et al., 2017;
Tang et al., 2019).
A similar rational has been used to enhance the efficacy
of photodynamic therapy (PDT) and photothermal therapy
(PTT). Liu et al. (2018b) used mesoporous silica coated gold
nanorods (AuNR@MSN) with 2,3-dimethylmaleic anhydride
(DMA)-modified chitosan oligosaccharide-block -poly (ethylene
glycol) polymer (CS(DMA)-PEG) as a pH sensitive polymer.
In presence of acidic pH, the amide bonds between CS and
DMA are broken and the RLA ([RLARLAR]2) peptide is
exposed to facilitate cellular internalization and mitochondrial
accumulation. In addition, AuNR@MSM is also loaded with
indocyanine green (ICG), a photosensitizer. Since the pH trigger
allows for tumor targeting and selective internalization, upon
laser irradiation both therapeutic approaches are active: (i) PDT
triggers the production of ROS that will hamper cell viability;
and (ii) PTT leads to heat generation that kills cancer cells
in a selective way. The combination of these two approaches
allows an enhanced therapeutic effect and lower side effects
due to the guided TME accumulation (Liu et al., 2018b).
Other have developed a system relying on self-assembly AuNPs
through dithiol-polyethylene glycol (HS-PEG-SH) molecules
that allow NP cross-linking. AuNPs are functionalized also with
Doxorubicin (DOX), bonded through the hydrazone-thiol group,
and an epidermal growth factor (EGF) peptide to act as an active
targeting moiety to cancer cells overexpressing the EGF receptor.
Once in the TME, the acidic and redox environment disassembles
the complexes, and hydrolysis of the hydrazone bonds release the
DOX. Using an in vivo mouse model the self-assembled AuNPs
presented an increased accumulation at the TMEwhen compared
to solo AuNPs (Feng et al., 2017).
pH induced aggregation of metal nanoparticles may also
be used to enhance the efficacy of photothermal therapy (Li
et al., 2014; Dai et al., 2015). Similar to the concept described
above, Jung et al. (2013) used citraconic amide moieties to
trigger NP aggregation when within the acidic TME that
leads to the creation of hot spots for surface-enhanced Raman
scattering (SERS) imaging and shifts the absorption to the
near infrared (NIR) for concomitant PTT (Jung et al., 2013).
Another strategy that is based on TME induced NP aggregation
was assayed for simultaneous photoacoustic imaging (PAI) and
PTT (Yu et al., 2017). In this work, two types of AuNPs
coated with complementary single-strand DNA containing at
the pyridine-2-imine end an α-cyclodextrin (α-CD) were used.
The acidic TME leads to the protonation of pyridine-2-imine
triggering separation of the α-CD and allows aggregation
of AuNPs due to complementary base pairing. Aggregation
also favors the retention of AuNP at the TME, which can
then be used for selective intratumoral PAI and PTT (Yu
et al., 2017). Another approach based on the pH within
the TME combined PDT and a set of imaging techniques:
fluorescence, PAI, and magnetic resonance imaging (MRI) using
core-shell gold nanocages@manganese dioxide (AuNC@MnO2)
(Liang et al., 2018). The acidic TME triggers degradation
of the MnO2 shell, releasing O2 and Mn
2+, which causes
an enrichment of the environment (including the hypoxic
parts) with O2, thus potentiating the PDT. Upon irradiation,
the presence of O2, Mn
2+ and the AuNC itself allows for
concomitant use of PDT, PAI, MRI, and FL imaging, in what
is a multifunctional nanotheranostics. Besides the effective
production of ROS due to the PDT that causes cell death, the
events unleashed via this approach cause immunogenic cell death
through the damage-associated molecular patterns (DAMPs)
liberation and, consequently, dendritic cells maturation, which
leads to effector cells activation (e.g., CD8T cells, CD4T
cells, and NK cells). Once again, the response to the pH
stimulus permits selective TME targeting, improving efficacy
while decreasing undesired deleterious effects to neighboring
healthy tissues.
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TABLE 2 | Targeting strategies for AuNPs toward TME.
System name Nanoparticle
(type)
TME component Diagnostics Therapeutics 3D in vitro/in vivo model References
“Smart” AuNPs (SANs) AuNP Acidic pH PAI Xenograft mouse model Song et al., 2016
c(RGDyK)-
MHDA/LSC@AuNP
AuNP Acidic pH PAI Xenograft mouse model Li et al., 2019
LGAuNP AuNP Acidic pH FLimaging Xenograft mouse model Lai et al., 2017
GNPs-CKL-FA AuNP Acidic pH FLimaging Xenograft bearing mice model Tang et al., 2019
AuNR@
MSN-RLA/CS(DMA)-PEG
AuNR Acidic pH PDT;
PTT
Xenograft bearing mice model Liu et al., 2018b
DOX-EGF-SA-AuNP AuNP Acidic pH DD Xenograft mouse model Feng et al., 2017
MC-GNPs AuNP Acidic pH PTT Li et al., 2014
pH-GSNPs Gold Shell
nanoparticles
Acidic pH PTT; DD Dai et al., 2015
MBA/SMART-AuNP AuNP Acidic pH SERS
imaging
PTT Jung et al., 2013
Gold nanomachines AuNP Acidic pH PAI PTT Xenograft mouse model Yu et al., 2017







PDT Xenograft mouse model Liang et al., 2018
V7-CMG AuNR Acidic pH MSOT DD Xenograft mouse model Zeiderman et al., 2016
Nanoprobe AuNP MMP-2; MMP-7 FLimaging Wang et al., 2012
MMP-sensitive AuNP probe AuNP MMP NIRF
tomographic
imaging
Xenograft mouse model Lee et al., 2008
MMP-GC-AuNPs AuNP MMP CT;
FLimaging
Xenograft bearing mice model Sun et al., 2011
G-AuNPs-DOX-PEG AuNP MMP-2
Acidic pH
DD Xenograft bearing mice model Ruan et al., 2015a
DOX-GLT/EGCG AuNPs AuNP MMP FLimaging DD Tsai et al., 2016
G-AuNPs-DC-RRGD AuNP MMP-2;
Acidic pH
FLimaging DD Xenograft bearing mice model;
Spheroid
Ruan et al., 2015b
DOX-substrate/AuNP AuNP MMP-2 FLimaging DD Xenograft bearing mice model Chen et al., 2013




Xenograft bearing mice model Xia et al., 2018
Au@BSA-NHA AuNP Hypoxia CT Xenograft bearing mice model Shi et al., 2016
Au-PCM-AIDH AuNC Hypoxia PTT; Free
Radicals





DD Spheroid Shabana et al., 2018
AuNP, spherical gold nanoparticles; AuNR, gold nanorods; AuNC, gold nanocages; SERS imaging, Surface-enhanced Raman scattering imaging; PTT, photothermal therapy; FLimaging,
Fluorescence imaging; MRI, magnetic resonance imaging; PAI, photoacoustic imaging, PDT, photodynamic therapy; MMP, matrix metalloproteinases; MMP-2, matrix metalloproteinases;
NIRF tomografic imaging, near infrared fluorescence imaging; CT, computed tomography; DD, drug delivery; DOX, doxorubicin; PCM, phase-change material.
Gold nanorods (AuNR) coated with mesoporous silica
capped with chitosan have been used as PAI contrast agent
for Multispectral Optoacoustic Tomography (MSOT) after
NIR excitation (Zeiderman et al., 2016). For active targeting,
these nanoconjugates were grafted with a pH sensitive variant
7 pHLIP peptide that allows specific accumulation at the
tumor site. These AuNRs may also convey a cargo of
chemotherapy (gemcitabine, a pyrimidine analog), where the
TME acidic pH protonates the amino groups of chitosan,
causing chitosan swelling (proton sponge) with consequent
gemcitabine dissociation and release from the mesoporous
silica (Zeiderman et al., 2016).
The Case for the Matrix Metalloproteinases
(MMP)
The increased expression of MMPs have an important role
in tumor progression and the substrate of these proteinases
can be used to selectively target nanomedicines to the
TME. For example, these substrates conjugated to dyes
coupled to AuNPs have been used as probes for imaging
of cancer sites toward diagnostic applications (Wang et al.,
2012). Since MMP-2 and MMP-7 are overexpressed in
multiple tumors, the authors designed AuNPs functionalized
with a peptide spacer that contains an MMP-2 substrate
(Gly-Pro-Leu-Gly-Val-Arg-Gly) and an MMP-7 substrate
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(Val-Pro-Leu-Ser-Leu-Thr-Met-Gly). The N-terminus







the C-terminus has attached to a 7-amino-4-methylcoumarin
(AMC), which may be hydrolyzed by one or both MMPs within
the TME, and fluorescence emission of dyes occurs. This results
in differences in fluorescence emission between cancer and
normal cells that may be used for imaging (Wang et al., 2012).
Lee et al. (2008) functionalized AuNPs with Cy5.5 dye attached
to a peptide (Gly-Pro-Leu-Gly-Val-Arg-Gly-Cys) that contains
the substrate for MMP (Pro-LeuGly-Val-Arg). Once in the TME,
the substrate is recognized and cleaved by the proteases, causing
dequenching of the dye and the near infrared fluorescence
(NIRF) signal may be assessed via NIRF tomographic imaging
(Lee et al., 2008). Sun et al. (2011) also used Cy5.5 dye linked
to the same substrate for MMP but in a different peptide to
develop a computed tomography (CT) contrast probe that may
simultaneously be assessed by NIRF. The AuNPs were coupled
with glycol chitosan polymers, which have shown excellent
stability and tumor targeting ability by EPR, and an organic dark
quencher. Upon MNP proteolysis, the dye is released and NIR
fluorescence emission may be detected. As such, it is possible
to obtain CT and NIRF images to provide anatomical and
MMP-dependent biological data of the TME (Sun et al., 2011).
Gelatin is another substrate for MMP, particularly for MPP-
2. Ruan et al. created a system for drug delivery relying on a
gelatin nanoparticle decorated with small AuNPs (Ruan et al.,
2015b). The AuNP surface is loaded with DOX linked by
hydrazone bonds that are hydrolyzed when in the acidic TME
medium.When the G-AuNPs-DOX-PEG nanoconjugate reaches
the TME, the gelatin nanoparticles are degraded by the MPP-2,
and the AuNPs-DOX-PEG released into the microenvironment.
Once free, these smaller nanocarriers may reach deeper into
the tumor and, due to the acidic microenvironment, DOX is
released leading to a more efficacious anti-tumor effect. In
another study, the same system was improved by addition of
two components: a tandem peptide, RRGD, and Cy5.5 dye
attached by hydrazone bonds to the AuNPs’ surface. The RRGD
peptide allows the active targeting to overexpressed integrin αvβ3
receptor and enhances the penetration capability of the system.
The Cy5.5 is release together with DOX by hydrolyze of the
hydrazone bonds in the acidic TME, permitting the visualization
via fluorescence imaging. The released small AuNPs are capable
of deeper tissue penetration, leading to accumulation at the
target and colocalization of Cy5.5 and DOX, in what can be
considered a two-stage multifunctional nanotheranostics system
(Ruan et al., 2015a).
Relying on the fluorescence emission of DOX, Chen and
co-workers developed a nanotheranostics system using AuNPs
with DOX attached to the surface via a protease substrate (Ac-
Cys-Pro-Leu-Gly-Leu-Ala-Gly-Gly-DOX) (Chen et al., 2013).
Within the TME, MMP-2 cleaves the ligation and DOX
is released, exerting its cytotoxic effect while proving for
fluorescence imaging selectively within the TME. Another
nanotheranostics system combining two therapeutic modalities,
PDT and chemotherapy, coupled to fluorescence imaging
has been developed using gold nanoclusters conjugated with
an MMP-2 substrate (Cys-Pro-Leu-Gly-Val-Arg-Gly-Arg-Gly-
Asp-Ser), and DOX bonded to cis-aconitic anhydride and a
photosensitizer chlorin e6 (Ce6) (Xia et al., 2018). The MMP-
2 substrate acts as active targeting to the TME due to the
overexpression of metalloproteinases and the cis-aconityl linkage
allows for controlled release of DOX on site due to the tumor
acidic hydrolyzed of the bonds. The photosensitizer allows
for PDT and imaging through fluorescence. The effect of this
nanoconjugate in tumor-bearing mice show great promise,
showing an enhanced anti-tumor effect when compared to free
DOX and AuNPs without the MMP-2 substrate.
Impact of ECM Components
The increased desmoplasia that frequently occur at the TME
may result in poor distribution of AuNPs inside the tumor
(Whilhelm et al., 2016). In an attempt of improving drug
delivery into the tumor, Abdolahinia et al. analyzed the effect
of AuNPs conjugated with collagenase (Col-AuNPs) combined
with AuNPs conjugated with metformin (MET-AuNPs). They
observed an increased number of apoptotic cells in breast cancer
spheroids when simultaneously treated with Col-AuNPs and
MET-AuNPs, suggesting increased AuNPs penetration in the
spheroid (Abdolahinia et al., 2019). In another interesting study,
Han et al. developed gold nanoparticles coated with PEGylated
polyethylenimine and conjugated with all-trans retinoic acid
(ATRA) and siRNA targeting heat shock protein 47 (HSP47)
envisaging the activation of pancreatic stellate cells (PSC).
With this pH responsive nanosystem, they were able to induce
PSC quiescence (through ATRA) and inhibit ECM desmoplasia
(through silencing of HSP47, a collagen-specific molecular
chaperone) (Han et al., 2018). Interestingly, a study performed
by Zhao et al. revealed that naked AuNPs were effective in
decreasing the TME desmoplasia of colorectal cancer xerograft
mice, by reducing the production of collagen I and diminishing
the expression of profibrotic signals (Zhao et al., 2018).
Hyaluronic acid, a linear anionic polymer found in the
connective, epithelial, and neural tissues has been widely used
in the clinics for arthritis treatment, ophthalmic surgery, tissue
engineering, and even drug delivery (Oh et al., 2010; Kim et al.,
2019). Due to the presence of carboxylic acid, hydroxyl and
N-acetyl groups, HA is easily combined with other chemicals.
Moreover, the selective transfer of HA to the tumor location
due to EPR effect, coupled to its connection with TME cellular
receptors, including cluster determinant CD44, receptor for HA-
mediated motility (RHAMM), and lymphatic vessel endothelial
receptor-1 (LYVE-1), makes this molecule suitable for improving
targeted nanomedicine (reviewed in Kim et al., 2019 and
references therein). More recent reports describe the production
of nanoconjugates for combined photothermal therapy (Liu R.
et al., 2019; Yang et al., 2019). Liu et al. proposed to use cationic
small sized red emission gold nanoclusters coated with BSA
and conjugated with indocyanine green as imaging probe for
theranostic and HA for increased retention at the tumor location
(AuNC@CBSA-ICG@HA) (Liu R. et al., 2019). An in vivo study
using mice breast cancer model revealed a suppression of 95%
of tumor growth (Liu R. et al., 2019). Yang et al. proposed a
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nanotheranostics platform based on gold nanoclusters combined
with graphene oxide and conjugated withHA, 5-fluorouracil. The
enzymatic degradation of HA at the TME by the hyaluronidases
allow the release of 5-fluorouracil, that, together with laser
irradiation, enhance the anti-tumor efficacy (Yang et al., 2019).
Making Use of Hypoxia for Selective
Targeting to the TME
The hypoxic TME has an active role in tumorigenesis and has
been shown to be a crucial factor in the lack of response to
some therapies and cancer drug resistance. As such, it may
be considered both as a critical element for selective action
within the TME and as an important target for therapy and
diagnostics. For example, Shi and co-workers presented a gold
nanoprobe for CT imaging responsive to hypoxia through the
conjugation of nitroimidazole moiety to AuNPs (Shi et al.,
2016). Under hypoxia, the nitro group of nitroimidazole is
reduced by nitroreductase, an enzyme present at elevated levels
in the TME, and the resultant reactive amide group will
bind to macromolecules within the TME leading to on site
accumulation. The AuNPs are coated with bovine serum albumin
(BSA) for increased colloidal stability, water solubility and
biocompatibility. This technique enhances the contrast attained
in CT imaging allowing for visualization of different intratumoral
hypoxic levels which can be helpful to disease prognosis. Others
have used AuNCs loaded with 2,2
′
-azobis[2-(2-imidazolin-2-
yl) propane] dihydrochloride (AIPH) coated by a phase-change
material, which allows the hypoxic cancer cells death through
the oxygen independent production of free-radicals (Shen et al.,
2017). After NIR irradiation, the photothermal effect of AuNC
triggers the melting of the coating and, consequent AIPH
release. Once free, AIPH decomposes due to thermal/irradiation
stimulation and alkyl radicals are generated, that in turn cause
oxidation of cell components oxidation and increased lipid
hydroperoxides, which will induce apoptosis. This concept allows
for the destruction of cells in hypoxic tumors and can be applied
in combination with photothermal therapy. Shabana et al. took
advantage of carbonic anhydrase IX (CA IX) overexpression that
occurs in hypoxic TME to develop AuNPs functionalized with
DOX and a CA inhibitor ligand, that allows active targeting to
hypoxic tumors (Shabana et al., 2018). DOX is grafted to the NPs
through a hydrazone group that is cleaved in acidic pH, releasing
the drug. This way, it is possible to selectively target the TME
to tackle the hypoxia-induced chemoresistance with improved
tumor penetration of the drug.
Synergistic Approach With the TME
Immune System
Immune cells in the TME play an important role in tumor
surveillance and development. The immune system behaves
differently within the TME and its differential modulation also
modifies the TME itself and can thus be used to improve therapy.
Some strategies have been described that use AuNPs to modulate
the immune system in the TME. For instance, AuNPs coated with
mouse serum albumin (MSA) induce the production of ROS and
reactive nitrogen species (RNS) that activate pro-inflammatory
pathways in TAMs (Pal et al., 2016). As a consequence, the
production of TNF-α and IL-10 is decreased and the production
of the pro-inflammatory cytokine IL-12 increased. These changes
triggered by AuNPs lead to a polarization of TAMs from an
M2 phenotype to an M1 phenotype (pro-inflammatory). These
changes in TAMs were also observed for a gold-manganese oxide
nanocomposite stabilized with MSA, where the manganese oxide
permits the enhancement ofmagnetic resonance of the agent and,
as a result, allows its use as a contrast agent inmagnetic resonance
imaging (MRI). In another approach, AuNPs functionalized with
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
that belongs to tumor necrosis factor (TNF) superfamily have
also been used to actively targetM2macrophages within the TME
(Huang and Hsu, 2017). The AuNPs bind to M2 macrophages
due to the binding of TRAIL to the cell surface death receptor
4 (DR4) and death receptor 5 (DR5), which activates a caspase-
dependent extrinsic apoptosis pathway and, consequently, cancer
cell death in a specific way. AuNPs have also been used as a carrier
for tumor-associated self-antigens that elicit the maturation of
dendritic cells and T cells proliferation (Ahn et al., 2014; Fogli
et al., 2017). Also, galactofuranose-coated AuNPs demonstrated
the capability to stimulate the maturation of dendritic cells and,
thus, promote a pro-inflammatory response (Chiodo et al., 2014).
The modulation of TAMs, dendritic cells and T cells indicate to
be suitable strategies to modulate the immune response within
the TME against cancer cells so as to hamper tumor progression.
Addressing Angiogenesis
The growth of new blood vessels from preexisting vessels is
essential for tumor expansion and to modulate TME, increasing
the levels of oxygen, nutrients, and decreasing toxic metabolites
(De Palma et al., 2017). In this respect, AuNPs have been
shown to be capable not only to disrupt signal transduction
from tumor mesenchymal cells to epithelial cells, but also to
inhibit angiogenic phenotypes in vitro (Zhang Y. et al., 2019).
Among the various VEGF subtypes, isoform VEGF165 is a
heparin binding protein and perhaps the most potent cytokine
in angiogenic process (Mukherjee et al., 2005; Arvizo et al.,
2011). By binding to tyrosine kinase receptor VEGFR-2, a signal
cascade is initiated, ultimately leading to the proliferation and
migration of endothelial cells and resulting in angiogenesis.
As such, therapeutic antibodies targeting VEGF165 have been
developed and are currently applied in the clinics to inhibit
the VEGF165 cascade activation (Ferrara and Kerbel, 2005).
Also, non-functionalized AuNPs are capable to inhibit of pro-
angiogenic heparin-binding growth factors (HB-GFs), such as
VEGF165, basic fibroblast growth factors (bFGFs), and placental
growth factor (PlGF) (Ferrara and Kerbel, 2005). The surface of
AuNPs inhibits HB-GFs by inducing changes in conformation
but, remarkably, AuNPs do not affect the activity of non-
HB-GFs, such as VEGF121 and EGF. These observations have
been corroborated in vivo, where VEGF/vascular permeability
factor (VPF) stimulated permeability was inhibited by AuNPs
(Mukherjee et al., 2005; Arvizo et al., 2011). AuNPs may also
influence angiogenesis by diminishing the tube formation and
the migration of endothelial cells through blockage of the VEGF-
VEGFR2 signaling in TME cells (Zhang Y. et al., 2019). What
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is more, AuNPs have been able to promote tumor vasculature
normalization while increasing blood perfusion and reducing
hypoxia (Li et al., 2017).
Not only “naked” AuNPs but also AuNP-conjugates have
been used as modulators of angiogenesis. Recombinant human
endostatin is an anti-angiogenic agent used for tumor treatment
that has been coupled to AuNPs to reduce cell migration
and tube formation in vitro (HUVECs), induced by anterior
gradient 2 (AGR2) (Pan et al., 2017). AGR2 is one of the latent
tumor angiogenesis factors, which has been mostly related to
tumor cell proliferation, transformation, migration and drug
resistance. In vivo metastatic colorectal cancer xenografts have
shown that recombinant human endostatin–AuNP are capable
to increase pericyte expression while inhibiting VEGFR2 and
anterior gradient 2. As such, these nanoconjugates might be
used to normalize tumor vessels using AGR2 as an anti-
angiogenic tumor target. Additional work by the Kanaras group
has demonstrated the enhanced effect of peptides, designed to
selectively interact with VEGFR1, for inhibition of angiogenesis
when grafted onto AuNPs (Bartczak et al., 2013, 2015; Millar
and Kanaras, 2013). This gold-nanoconjugates can influence the
extent and morphology of vascular structures, without causing
toxicity (Bartczak et al., 2013, 2015; Millar and Kanaras, 2013). By
exposing a chicken chorioallantoicmembrane to the sameAuNP-
peptide, the same effect was observed in vivo (Roma-Rodrigues
et al., 2016), but could be tremendously enhanced by irradiating
the nanoformulation with a green laser, which simultaneously
allowed to cauterize emerging blood vessels with extreme spatial
precision, and prevented neo-vascularization (Pedrosa et al.,
2017). These studies highlighted the role of the VEGFR1
dependent pathways in the process, which were downregulated
by the nanoformulation with and without irradiation (Pedrosa
et al., 2017). These studies show that AuNPs can be used to
alter the expression of anti-angiogenic factors, under biological
conditions, and may be a valuable tool to tackle the angiogenesis
within the TME.
The Role for TME Derived Exosomes
The role of exosomes in TME maturation combined with
their stability in body fluids, have made these nanovesicles
as promising agents in cancer management. There have been
several studies reporting on the use of AuNPs for therapy and
diagnostics (nanotheranostics) (see Roma-Rodrigues et al., 2017b
for extended discussion). The developmental and metabolic state
of each cell is reflected on exosome production, trafficking and
the exosomes’ own content. What is more, after entering the
circulatory system, TME derived exosomes have been proposed
as valuable cancer biomarkers, particularly when referring the
use of liquid biopsies. Nevertheless, the direct diagnostics using
exosomes, is hampered by the low concentration of circulating
tumor cells derived exosomes (TCDEs) in the initial stages of
tumor progression. As such, Huang and co-workers designed
a dual-signal amplification platform for detection of exosomes
derived from leukemia cells (Huang et al., 2018). The detection
system consisted in three steps: (i) the high abundance of
the tetraspanin CD63 at the exosome membrane was used
to capture the vesicles using anti-CD63 antibodies conjugated
to magnetic beads; (ii) the highly abundant nucleolin at the
surface of exosomes was used as target to bind the vesicles to a
nucleolin-recognition aptamer (AS1411), allowing the initiation
of a rolling circle amplification (RCA) reaction; and (iii) the
resulting amplified sequences hybridize with AuNPs conjugated
with a specific oligonucleotide and a quenched fluorescent dye
(FAM), which, via the action of an endonuclease, will result
in FAM release and concomitant emission of fluorescence.
With this platform, it was possible to detect exosomes in a
spiked serum sample with high sensitivity. Others have used
a SERS-based biosensors by modifying the surface of gold
nanostars@4-mercaptobenzoic acid@nanoshell structures with
bivalent cholesterol- labeled DNA anchor (Tian et al., 2018).
After capturing exosomes with magnetic beads containing CD-9
antibody, the SERS biosensors were fixed at the exosome surface
through hydrophobic interactions between the cholesterol
present in the beads and the lipidic membrane of the vesicles.
When assembled to the exosomes, a SERS signal could be attained
for improved detection. Also focused on SERS, a screening
platform using capturing substrates, consisting in gold shell
magnetic nanobeads conjugated with aptamers for recognition
of CD63 at the surface of exosomes, and in SERS probes with
three distinct Raman reporters was proposed (Wang Z. et al.,
2018). With this technology, it was possible to detect distinct
types of exosomes in blood samples, rendering this methodology
as promising for diagnosis of early stage cancer.
Also, one the most important characteristics of exosomes is
their role in transport of virus, chemotherapeutic agents, DNA
and proteins, making them promising vectors for cancer therapy
(reviewed in Srivastava et al., 2016). Recent studies describe the
transport of AuNPs by exosomes derived from different types
of cells, including macrophages and breast cancer cells (Roma-
Rodrigues et al., 2017a; Logozzi et al., 2019). Taking advantage
of this feature, Sancho-Albero et al. loaded MSCs with hollow
AuNPs and revealed a selective transfer of the exosome-cargo
into cells of the same type than that of the cell of origin. It was
then proposed to apply this preferential uptake conjugated with
light-induced hyperthermia for anti-cancer therapy (Sancho-
Albero et al., 2019).
Taking Advantage of Folate Requirements
of Tumor Cells for Active Targeting
As already mentioned in section Tumor Microenvironment,
the high proliferation rate of tumor cells demands a higher
nutritional supply, resulting in the increased expression of
nutrient receptors, such as folic acid receptors (or folate) to
respond to the high request of folate for DNA synthesis (Farran
et al., 2019). The functionalization of AuNPs with folate has
showed a great potential for increased AuNPs targeting in cancer
(reviewed in Samadian et al., 2016; Beik et al., 2017). Several
groups have proposed gold nanostructures functionalized with
PEG conjugated with folate for photothermal therapy (Ghaznavi
et al., 2018;Wang J. et al., 2018;Majidi et al., 2019). Ghaznavi et al.
(2018) developed gold and iron oxide core-shell nanoparticles
coated with PEG conjugated with folate (FA-PEG-Au@IONP),
Majidi et al. synthesized silica and gold core-shell nanoparticles
with folate (FA-SiO2@AuNPs) and Wang et al. proposed a gold
nanostars-based nanocomposites conjugated with a fluorescent
polypeptide for image-guided therapy. Zeinizade et al. analyzed
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 12 August 2019 | Volume 7 | Article 197
Roma-Rodrigues et al. Nanotheranostics Targeting TME
the effect of folate conjugated AuNPs. In these four reports,
increased apoptosis was observed only when tumor cells were
simultaneously treated with nanoconjugates and laser irradiation
(Ghaznavi et al., 2018; Wang J. et al., 2018; Zeinizade et al.,
2018; Majidi et al., 2019). With the same objective, Wang
et al. designed multi-layered single walled carbon nanotubes
consisting in single walled carbon nanotubes coated with
BSA and functionalized with PEG conjugated with folate and
with doxorubicin (SWNT@BSA@Au-S-PEG-FA@DOX). The
treatment of mice bearing tumors with nanoconjugates and near
infrared laser (808 nm) resulted in complete tumor eradication
with negligible damage of normal tissues (Wang D. et al.,
2018). Zhao et al. developed gold nanochains with worm
like structures as a light-triggered system for photodynamic
therapy and multiplex detection. These gold nanochains were
synthesized using hyaluronic acid-hydrocaffeic acid conjugates as
templates and Raman reporters, photosensitizers and folate for
active targeting. They observed that low concentrations of these
nanoconjugates result in high selectivity and phototoxicity after
laser irradiation (Zhao et al., 2019).
Other groups have proposed gold-based nanocomposites
conjugated with folate for imaging purposes. Beik et al. analyzed
with detail the effect of AuNPs conjugated with folate for
CT with the advantage of using lower dosage and enhanced
image contrast (Beik et al., 2018). Kumar et al. used green
synthesis to prepare gum kondagogu capped gold nanoparticles
coupled to folate and fluorescein isothiocyanate (FITC) and
observed a high affinity of nanoconjugates toward folate receptor
positive cells (Kumar et al., 2018). In another approach, Zhang
et al. synthesized mesoporous carbon-gold hybrid nanozyme
nanoprobes stabilized with BSA and folate and loaded with
IR780 iodide (OMCAPs@rBSA-FA@IR780). In vivo analysis
revealed efficient tumor targeting and retention (Zhang A. et al.,
2019). Khademi et al. studied the in vivo targeting of AuNPs
conjugated with folate through cysteamine (FA-Cys-AuNPs)
for nasopharyngeal head and neck cancer, which were judged
suitable for use as contrast agents in CT scan imaging (Khademi
et al., 2019).
CONCLUSIONS
In the past, cancer, and tumor development have been considered
alone almost as if a strange body to the host organism.
Nowadays, tumorigeneses and development must be considered
as an element within a larger context that modulates itself
in a continuous process of cell progression and maturation.
The tumor micro-environment constitutes that differentiating
niche where clonal expansion is possible through a multitude of
molecular inputs that are at the basis of cancer heterogeneity.
Notwithstanding the exponential development of therapeutic
approaches to tackle these niches, there has been a growing
need to combine several modes of action and therapy modalities
simultaneously to tackle the TME. Nanomedicine has been
providing for a plethora of multi-functional platforms capable
of conveying different cargos to the site of interest in a selective
way, while simultaneously providing for diagnostics, imaging
and/or biodistribution capability, toward earlier detection, and
destruction of cancer cells. These nanotheranostics systems
have relied heavily on gold nanoparticles due to their chemical
versatility, biocompatibility and unique spectral properties. This
way, making use of the specific conditions within the TME,
it has been possible to develop bio responsive platforms to
selectively address this particular cellular context. AuNPs have
been engineered so as to tackle and/or profit from particular
aspects of the TME toward a more selective targeting of the
tumor site, or a focal delivery of the therapeutic cargo, and/or
to accumulate the nanoconjugates at a precise location that
potentiates the use of photoinduced therapies based on the
spectral properties of AuNPs.
Still, there are several issues that need to be addressed. Despite
the growing number of in vitro modeling systems, these are still
not equivalent to the real TME. Usually these in vitro models, be
it the 3D co-cultures and/or on-chip platforms, do not address
more than three to four types of cells embedded in an unchanging
support media/scaffold. As such, one only gets a couple of
photograms from the evolving context of the TME film. These
photograms provide valuable information to address a particular
factor and/or pathway in a hierarchized hypothesis rather than
the whole TME. Nevertheless, the possibility to link and associate
several of these models into more complex and interconnected
chip systems may provide for systems that more closely resemble
what is happening in the TME in vivo, and that researchers
only now start to get a deeper understanding of events. These
models, despite their actual limitations, have been providing for
valuable tools to screen and develop new approaches to study
and tackle the TME. Here, innovative nanomedicines have taken
the lead in making use of the conditions and characteristics of
the TME to deliver therapeutics with increasing precision, while
providing for signal outputs that allow to follow their effect in real
time—real nanotheranostics platforms.
These nanotheranostics strategies may be combined in
approaches that simultaneously profit from distinct features of
the TME for potentiating the active targeting, controlled release,
and therapy modality coupled to imaging/diagnostics. As such,
the combination of these features may provide for valuable
tools to tackle the TME, addressing the tumor heterogeneity,
decreasing tumor resistance, and bringing more efficacious
strategies to the clinics.
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